You just read:

Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease

News provided by

Bausch Health Companies Inc.

Apr 25, 2019, 07:00 ET